368 related articles for article (PubMed ID: 32005261)
41. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
[TBL] [Abstract][Full Text] [Related]
42. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
[TBL] [Abstract][Full Text] [Related]
43. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Dewaele B; Wasag B; Cools J; Sciot R; Prenen H; Vandenberghe P; Wozniak A; Schöffski P; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2008 Sep; 14(18):5749-58. PubMed ID: 18794084
[TBL] [Abstract][Full Text] [Related]
44. Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis.
Wu Y; Gao B; Xia Q; Zhu Y; Wang N; Chang X; Huang B; Luo D; Zhang J; Zhang P; Shi H; Fan J; Nie X
World J Surg Oncol; 2023 Apr; 21(1):138. PubMed ID: 37120571
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
[TBL] [Abstract][Full Text] [Related]
46. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
47. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
Medeiros F; Corless CL; Duensing A; Hornick JL; Oliveira AM; Heinrich MC; Fletcher JA; Fletcher CD
Am J Surg Pathol; 2004 Jul; 28(7):889-94. PubMed ID: 15223958
[TBL] [Abstract][Full Text] [Related]
48. Long-term response to pimitespib in postoperative recurrent gastrointestinal stromal tumors with PDGFRA D842V mutation: a case report.
Teranishi R; Takahashi T; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Eguchi H; Doki Y
Surg Case Rep; 2023 Apr; 9(1):54. PubMed ID: 37027098
[TBL] [Abstract][Full Text] [Related]
49. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
50. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
[TBL] [Abstract][Full Text] [Related]
51. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
52. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Senchak J; Ahr K; von Mehren M
Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
[TBL] [Abstract][Full Text] [Related]
53. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
Front Immunol; 2020; 11():851. PubMed ID: 32670260
[TBL] [Abstract][Full Text] [Related]
54. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.
Dileo P; Pricl S; Tamborini E; Negri T; Stacchiotti S; Gronchi A; Posocco P; Laurini E; Coco P; Fumagalli E; Casali PG; Pilotti S
Int J Cancer; 2011 Feb; 128(4):983-90. PubMed ID: 20473908
[TBL] [Abstract][Full Text] [Related]
55. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
56. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
57. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
58. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
[TBL] [Abstract][Full Text] [Related]
59. Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.
Henriques-Abreu M; Serrano C
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1081-1088. PubMed ID: 34404327
[TBL] [Abstract][Full Text] [Related]
60. Correlation of treatment outcome in sanger/RT‑qPCR
Unk M; Bombač A; Jezeršek Novaković B; Stegel V; Šetrajčič Dragoš V; Blatnik O; Klančar G; Novaković S
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35904169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
